Details

Autor(en) / Beteiligte

• Queiroz, Ana Carolina Matos
• Fabri, Vanessa
• Mantoan, Henrique
• Sanches, Solange Moraes
• Guimarães, Andréia Paiva Gadelha
• Ribeiro, Adriana Regina Gonçalves
• da Nogueira Silveira Lima, João Paulo
• Chen, Michael Jenwel
• Baiocchi, Glauco
• da Costa, Alexandre André Balieiro Anastácio

Titel

Risk factors for pelvic and distant recurrence in locally advanced cervical cancer

Ist Teil von

• European journal of obstetrics & gynecology and reproductive biology, 2019-04, Vol.235, p.6-12

Ort / Verlag

Ireland: Elsevier B.V

Erscheinungsjahr

2019

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Despite the benefits of concomitant radiotherapy and cisplatin for locally advanced cervical cancer, recurrence rates remain high. New treatment strategies such as consolidation chemotherapy and different concomitant chemotherapy combinations have been tested in recent years. Identification of the best candidates for each treatment strategy could optimize results. A retrospective review of data from 127 patients with locally advanced cervical cancer (International Federation of Gynecology and Obstetrics Stages IIB–IVA), treated at a single institution from 2005 to 2014. Risk factors for loco-regional and systemic recurrence, and prognostic factors for overall survival (OS) were analysed using Cox regression. Survival of patients treated with consolidation chemotherapy was compared with survival of patients not treated with consolidation chemotherapy in the role cohort and in a propensity-score-matched cohort. With a median follow-up time of 48.7 months, loco-regional-recurrence-free survival (LRFS), distant-metastasis-free survival (DMFS) and OS at 5 years were 76.6%, 54.0% and 63.0%, respectively. On multivariate analysis, tumour size ≥6 cm was associated with shorter LRFS [hazard ratio (HR) 5.18; 95% confidence interval (CI) 1.45–18.45; p = 0.011], and adenocarcinoma (HR 2.48; 95% CI 1.10–5.57; p = 0.028) and positive lymph nodes (HR 2.21; 95% CI 1.303–4.72; p = 0.041) were associated with shorter DMFS. Tumour size ≥6 cm was associated with shorter OS (HR 2.64; 95% CI 1.09–6.35; p = 0.031). Twenty-two patients were treated with consolidation chemotherapy; on univariate analysis, these patients had longer OS compared with patients who were not treated with consolidation chemotherapy (p = 0.043). In a propensity-score-matched cohort, patients treated with consolidation chemotherapy had longer DMFS and OS compared with patients who were not treated with consolidation chemotherapy, although the difference was not significant. Different risk factors are associated with loco-regional and distant metastases in patients with locally advanced cervical cancer, and could potentially lead to particular therapeutic strategies. Although the number of patients treated with consolidation chemotherapy in the study cohort was small, they seemed to live longer and to have better control of distant relapse then patients who were not treated with consolidation chemotherapy.